Participated · Equity · Aug 2026

Databricks operates a cloud data platform and AI products, with its core cloud data warehouse generating $1.5 billion of its annualized run-rate revenue and growing 100% year-over-year. The company reported a $7 billion annualized run-rate revenue figure while growing at roughly 80% and being cash-flow positive. Databricks launched Lakebase in June 2025, which has reached a $100 million revenue run-rate, and its AI chatbot tool Genie is described as highly popular. The company maintains a roughly 100-person AI research team and faces multi-billion-dollar cloud commitments with major hyperscalers. Databricks has been active on the M&A front, acquiring companies including Electric (PGlite) and AI cybersecurity firm Panther, and it says it plans to continue investing in AI and acquisitions while remaining open to a future IPO.

Participated · Series H · May 2026

Anthropic is a premier artificial intelligence safety and research company renowned for developing Claude, a family of highly capable, steerable, and safe large language models. Founded by former OpenAI researchers, Anthropic pioneers techniques like "Constitutional AI" to build systems that are helpful, honest, and harmless. Beyond its core research, the company has rapidly scaled into a dominant market force, experiencing exponential revenue growth driven by widespread enterprise adoption. Anthropic has attracted unprecedented investor attention, recently raising approximately $30 billion at a $380 billion valuation, with ongoing negotiations potentially boosting its valuation to roughly $800 billion. As a leading competitor in the generative AI space, the company is reportedly exploring an IPO later this year.

Participated · Series B · May 2026

Isomorphic Labs develops a unified AI drug design engine (IsoDDE) composed of proprietary foundational AI models intended to work across multiple therapeutic areas and drug modalities. The company says IsoDDE provides predictive fidelity that bridges structure prediction and real-world drug discovery and has already demonstrated progress across internal programs. Isomorphic Labs advances a portfolio of partnered programs and wholly-owned internal programs, and maintains strategic collaborations with Novartis, Lilly, and Johnson & Johnson. Following a $2.1 billion Series B, the company plans to scale its technology globally, expand its pipeline toward clinical candidates, and hire AI, engineering, drug design, and clinical talent. Founded in 2021, Isomorphic Labs is headquartered in London and has offices in Cambridge, Massachusetts and Lausanne, Switzerland.

Participated · Equity · Mar 2026

OpenAI develops advanced artificial intelligence products, including ChatGPT and APIs for developers. The company is establishing The Deployment Company via a strategic alliance with private-equity partners to drive deeper enterprise integration of its AI tools. OpenAI will retain majority control of the joint venture, which is capitalized with more than $4.0 billion from investors and valued at about $10.0 billion. The initiative emphasizes embedding "forward-deployed engineers" inside client organizations to tailor and implement solutions. Target industries for deployment include financial services, health care, manufacturing and logistics. The move is part of a broader shift toward monetization and scaling enterprise adoption as OpenAI and peers consider potential IPOs, and it follows an internal leadership shift assigning Brad Lightcap to oversee related market-facing projects.

Participated · Series E · Jan 2026

xAI develops state-of-the-art artificial-intelligence models and related platform technology, positioning itself as a frontier provider of advanced AI capabilities. The company’s Grok models are slated for deployment in Saudi Arabia through a 500 MW joint data-center and compute-infrastructure initiative with strategic partner HUMAIN. xAI is on the cusp of being acquired by SpaceX, a transaction that will marry its AI expertise with SpaceX’s global scale and engineering resources. The merger is expected to accelerate product integration and platform expansion across both terrestrial and space-oriented applications. Financially, xAI just closed a multi-billion-dollar Series E round, its final fundraising before the SpaceX acquisition, reinforcing investor confidence in its technology and growth trajectory. HUMAIN’s investment converts into SpaceX equity upon completion of the merger, providing continuity of long-term capital support for xAI’s roadmap.